MediGene, in co-operation with the British drug regulatory authority – Medicines and Healthcare Products Regulatory Agency, has conducted a series of in-vitro studies to rule out any potential detrimental interaction between RhuDex and arteriosclerotic blood vessels. RhuDex is intended for the treatment of rheumatoid arthritis.
RhuDex, originating from Active Biotech’s patented CD80 antagonists, is out-licensed to MediGene. RhuDex is being developed as a disease-modifying drug for the treatment of rheumatic diseases.
Reportedly, the results are now submitted to the regulatory authority for appraisal. The company said that upon approval, clinical development of the drug candidate would be resumed before the end of this year.